ImmunityBio, Inc. | LinkedIn (original) (raw)

About us

ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. The activation of the innate immune system is key to the development of immunological memory. Over the last two decades, our founder and Executive Chairman Dr. Patrick Soon-Shiong has investigated mechanisms to activate the immune system to attack tumors that can otherwise evade and escape the body’s defense mechanisms. After inventing the world’s first protein nanoparticle drug, Abraxane, Dr. Soon-Shiong turned his focus to the next generation of immunotherapies. ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious diseases. "At ImmunityBio, we envision a day when we no longer fear cancer but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease." -Dr. Patrick Soon-Shiong, Executive Chairman

Industry

Biotechnology Research

Company size

501-1,000 employees

Headquarters

San Diego, CA

Type

Public Company

Specialties

Immunotherapy, Cancer, Infectious Diseases, Natural Killer, T Cell, Vaccines, Oncology, Vaccine, Fusion Proteins, Clinical Trials, Manufacturing, COVID-19, Yeast, and Cell Therapy

Locations

Employees at ImmunityBio, Inc.

Updates

Join now to see what you are missing

Join now

Affiliated pages

Similar pages

Browse jobs

Funding